LOYCE MOFOR: Open Payments
NPI 1912451394 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,232 in 12 payments from 8 companies in 2025. Trend: 2023 $880 · 2024 $912 · 2025 $1,232
Food & beverage: $1,232
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 3 | $363 |
| Corcept Therapeutics | 2 | $206 |
| Gilead Sciences, Inc. | 2 | $146 |
| Abbott Laboratories | 1 | $146 |
| ABBVIE INC. | 1 | $125 |
| Fresenius Kabi USA, LLC | 1 | $123 |
| Vantive US Healthcare LLC | 1 | $100 |
| Smith+Nephew, Inc. | 1 | $24 |
Products named: Korlym, Livdelzi, PROCLAIM, EMBLAVEO, Smoflipid, Renal - Acute, STRAVIX PL.
Industry payments across TX — which companies pay providers there.
